Extracts from the report on the Joint IGCC/IFRP East and South East Asia Seminar on Regional Fertility Research release_mieexhez6ndspk5hsyhw24tjxm

Abstract

The attempt is made to provide some answers on the use of Depo Provera. In the use of Depo Provera, the standard procedure is to give an injection of 150 mgs in 1 ml in an arm or hip muscle every 12 weeks, beginning soon after delivery or miscarriage or early in the menstrual cycle in the case of menstruating women. The outstanding attraction of the long-acting contraceptive injection in the minds of the 81,034 Chiang Mai acceptors is what can be described as the freedom from the fear of forgetting. The acceptors also enjoyed the ease and convenience of administration and the high effectiveness of the method. Of 142 women using this method for a year, on an average, only one woman will have an unexpected pregnancy. Depo Provera has a lower failure rate then IUDs, condoms, foams, jellies, or the "safe period," and it does not produce pelvic infection and inflammation wometimes seen with IUDs. It also does not effect breast milk in nursing mothers. The drawbacks to the use of the injectable contraceptive include amenorrhea, irregular menstrual periods, spotting, and sometimes heavy periods. Depo Provera also has other uses which include use in instances of threatened and habitual miscarriage and use in the treatment of endometriosis. Depo Provera is a safe method. Among the estimated 1 million or so users, there has not been a death caused by Depo Provera. Depo Provera has been approved for use in 10 European countries. The World Health Organization and the International Planned Parenthood Federation have approved the use of Depo Provera.
In text/plain format

Archived Content

There are no accessible files associated with this release. You could check other releases for this work for an accessible version.